Cardiff Oncology, Inc. (CRDF) Earnings History
Net Loss21 years of earnings data (2005–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Cardiff Oncology, Inc. (CRDF) Earnings Overview
As of June 12, 2026, Cardiff Oncology, Inc. (CRDF) reported trailing twelve-month net income of -$45M, reflecting +27.4% year-over-year growth. The company earned $-0.66 per diluted share over the past four quarters, with a net profit margin of -7732.0%.
Looking at the long-term picture, CRDF's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2011.
Cardiff Oncology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including TGTX ($462M net income, 72.6% margin), MGNX (-$70M net income, -49.9% margin), NKTR (-$158M net income, -297.1% margin), CRDF has room to improve margins relative to the peer group. Compare CRDF vs TGTX →
CRDF Earnings vs Peers
Earnings metrics vs comparable public companies
CRDF Historical Earnings Data (2005–2025)
18 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$46M | -0.9% | -$49M | $-0.69 | -7732.0% | -8256.3% |
| 2024 | -$45M | -9.6% | -$49M | $-0.95 | -6651.7% | -7123.1% |
| 2023 | -$41M | -7.1% | -$45M | $-0.93 | -8492.0% | -9305.7% |
| 2022 | -$39M | -36.8% | -$40M | $-0.89 | -10026.9% | -10337.3% |
| 2021 | -$28M | -46.5% | -$29M | $-0.73 | -7880.5% | -8037.6% |
| 2020 | -$19M | -17.6% | -$19M | $-1.08 | -5275.1% | -5214.8% |
| 2019 | -$16M | +0.3% | -$17M | $-2.70 | -6709.7% | -6817.8% |
| 2018 | -$16M | +33.9% | -$17M | $-7.06 | -4354.8% | -4511.4% |
| 2017 | -$25M | +36.5% | -$26M | $-51.71 | -4932.1% | -5068.5% |
| 2016 | -$39M | -42.7% | -$40M | $-93.22 | -10289.8% | -10536.7% |
| 2015 | -$27M | -91.8% | -$25M | $-74.77 | -8776.7% | -8074.8% |
| 2014 | -$14M | -21.3% | -$15M | $-54.08 | -5116.1% | -5337.5% |
| 2013 | -$12M | -2.1% | -$11M | $-50.09 | -4555.9% | -4123.7% |
| 2012 | -$12M | -416.5% | -$5M | $-63.73 | -2570.2% | -1077.6% |
| 2011 | -$2M | +58.9% | -$3M | $-16.60 | -868.9% | -1155.2% |
| 2010 | -$5M | -119.7% | -$5M | $-54.81 | -2051.1% | -2024.8% |
| 2009 | -$2M | +68.4% | -$2M | $-35.43 | -381.5% | -367.7% |
| 2005 | -$8M | - | -$8M | $-7.55 | - | - |
Download Data
Export CRDF earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in CRDF back in 2005?
Total return with dividends reinvested · 21+ years of data
Calculate ReturnsHow much would $100/month in CRDF be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs CRDF Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCRDF vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowCRDF — Frequently Asked Questions
Quick answers to the most common questions about buying CRDF stock.
What is CRDF earnings per share (EPS)?
CRDF trailing twelve-month (TTM) diluted EPS is $-0.66, reflecting +27.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2005 to 2025 is available in the table on this page.
What is Cardiff Oncology, Inc.'s net income?
Cardiff Oncology, Inc. (CRDF) trailing twelve-month net income is $-45M as of 2025. Earnings grew +27.4% year-over-year.
Is CRDF profitable?
CRDF is not currently profitable on a TTM basis, reporting a net loss of $-45M. Net margin is -7732.0%. Investors should monitor for a return to profitability.
What is CRDF's earnings growth rate?
CRDF compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2005 to 2025.
What are CRDF's profit margins?
Cardiff Oncology, Inc. net profit margin is -7732.0%, operating margin is -8256.3%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -71.5%.
Is CRDF growing earnings?
Yes, CRDF earnings are accelerating — EPS growth of +27.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-45M. Earnings momentum is strengthening.
What was CRDF's best earnings year?
Cardiff Oncology, Inc.'s highest annual net income on record is $-2M, achieved in fiscal year 2011. Earnings history on this page spans 2005 to 2025 and includes all annual and quarterly figures.
What were CRDF's earnings last quarter?
CRDF's most recent reported quarter was Q1 2026. Net income was $-12M with diluted EPS of $-0.18. For a full breakdown of all quarters, see the quarterly earnings table on this page.